ResMed Inc. (NYSE:RMD) is one of the best medical technology stocks to invest in. On January 30, KeyBanc Capital Markets lifted its price target on ResMed Inc. (NYSE:RMD) to $302 from $299 and maintained an Overweight rating.
KeyBanc described ResMed’s second-quarter fiscal 2026 results as largely positive and supportive of its overall investment thesis for the company. The firm highlighted that ResMed’s Q2 revenue exceeded expectations, and that strength was concentrated in two core hardware segments: the Masks & Accessories and Devices businesses. This strength, the analysts said, drove the outperformance and even offset the underwhelming figures from the company’s Software as a Service (SaaS) segment.
The analysts also expressed encouragement about ResMed’s decision to raise the low end of its gross margin guidance for fiscal 2026. To them, this move is evidence of improving profitability expectations for the remainder of the year despite already maintaining a healthy gross profit margin of 60.69%.
On the same day, January 30, RBC Capital Markets raised its price target on ResMed to $314 from $311. The firm left the Outperform rating on the stock unchanged.
RBC Capital raised ResMed’s price target after strong quarterly results. The company posted double‑digit growth in revenue and earnings, beating estimates. RBC highlighted solid performance across markets, improving margins, and operating leverage. It kept an Outperform rating, citing ResMed’s earnings outlook, fair valuation, and potential shareholder returns.
ResMed Inc. (NYSE:RMD) develops and manufactures medical devices and digital health solutions for sleep apnea, chronic obstructive pulmonary disease, and other respiratory conditions. Its products include CPAP machines, masks, and cloud-connected software platforms that enable remote patient monitoring and management.
While we acknowledge the potential of RMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 Best Foreign Stocks to Buy Right Now and 11 Best AI Penny Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
